Skip to main content
Bern researcher viewing sample)

Research & Development

Innovation is in Our DNA

Innovation has been in the DNA of CSL Behring since our beginning and continues as the core of everything we do today. Our team of over 2,000 R&D experts are dedicated to developing and delivering new therapies to solve unmet medical needs and save lives. We have created one of the largest and most efficient plasma collection networks in the world and strive to be the best at delivering safe and effective medicines for our patients.

  • US $1.16 billion

    was invested in R&D in 2021/22 across our businesses

  • US $4.6 billion

    in R&D investments in the last 5 years

  • >2,000

    research & development employees

Female Scientist at Broadmeadows

Investment in our R&D

Investment in R&D is an important driver for CSL Behring’s future growth. We have a high quality and potentially valuable portfolio of projects in various stages of development. We continue to make a balanced investment in the life cycle management and market development of existing products that bring short to mid-term commercial benefits, and we make strategic investments in longer term, higher risk and high opportunity new product development activities.

Find a Clinical Trial

A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants."

Therapeutic Area Condition Study
Description Status
(click on link to learn more)
Haematology & Thrombosis
Hemophilia A OPERA Register of Patients With haEmophilia A tReated With Afstyla® (OPERA) Active, Not Recruiting
Hemophilia B OrPHEe Observatory of Patients With Haemophilia B Treated by IdElvion® Recruiting
  Hemophilia B  CSL220_1002 Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B  Active, Not Recruiting
  Hemophilia B  CSL222_3001 HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
Active, Not Recruiting
Sickle Cell CSL889_1001 A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label,  Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients with Sickle Cell Disease
Von Willebrand Disease
OPALE Registry of Patients With Von WilLEbrand Disease Treated With Voncento® (OPALE)
Active, Not Recruiting
Cardiovascular and Metabolic Acute Coronary Syndrome CSL112_3001 Study to investigateCSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) Recruiting
  End Stage Kidney Disease  CSL300_2301  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis Not Yet Recruiting 
Diabetic Kidney Disease CSL346_2001 A Phase 2a Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal AntibodyCSL346in Subjects With Diabetic Kidney Disease Recruiting
Immunology and Neurology Dermatomyositis (DM) IgPro20_3007 A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with Dermatomyositis (DM) [RECLAIIM] Recruiting
Pediatric CIDP IgPro10_4002 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting
Hereditary Angioedema (HAE)
CSL312_3002 Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks Active, Not Recruiting
Hidradenitis Suppurativa and Palmoplantar Pustulosis CSL324_1002 A study of the safety and pharmacokinetics of repeat doses ofCSL324in subjects with hidradenitis suppurativa and palmoplantar pustulosis Active, Not Recruiting
Inflammatory Neuropathy pHeNIx
Hizentra® in Inflammatory Neuropathies - pHeNIx Study Recruiting
  Healthy Subjects  CSL312_1004 A Phase 1 Study to Compare the Pharmacokinetic Properties of CSL312 Administered by Subcutaneous Prefilled Syringe Assembled to Autoinjector to Prefilled Syringe Assembled to Needle Safety Device in Healthy Adult Subjects
Healthy Subjects CSL730_1002 A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SubcutaneousCSL730in Healthy Adult Subjects Recruiting
Respiratory Mild Asthma CSL311_1001 A Clinical Study to test the safety, exposure, and markers of Efficacy of CSL311 in patients with mild asthma. Recruiting
Idiopathic Pulmonary Fibrosis CSL312_2002 CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis Recruiting
Non-cystic Fibrosis Bronchiectasis (NCFB)
CSL787_1001 Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) Recruiting
alpha-1 antitrypsin deficiency
AmAREtTI Study
Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage)
Transplant Antibody-mediated kidney transplant rejection CSL300_3001 A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients [IMAGINE] Recruiting
Acute GVHD (aGVHD) CSL964_2001 The Safety and Efficacy of Alpha 1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant [MODULATE] Recruiting
Graft Versus Host Disease (GVHD) CSL964_5001 A study on theefficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD Recruiting
  Chronic Active Antibody Mediated Rejection AMR BoD Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection


COVID-19 COVID-19 CSL312_COVID-19 A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) Results
COVID-19 CSL324_COVID-19 CSL324 in COVID‑19 Withdrawn
COVID-19 CSL760_1001 Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects Cancelled
Haematology & Thrombosis
Reversal of acquired coagulation factor deficiency BE1116_4001
An Observational Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra®or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

Congenital Fibrinogen Deficiency BI3023_4003 An Observational Study of the Safety and Efficacy of Fibrinogen Concentrate Human (FCH) in Subjects With Congenital Fibrinogen Deficiency Completed
Hemophilia A
CSL627_3001 An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
  Hemophilia B CSL222_2001 Dose Confirmation Trial of AAV5-hFIXco-Padua
Hemophilia B CSL654_3001 A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
Hemophilia B CSL654_3002 A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B
Hemophilia B CSL654_3003 A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
  Hemophilia B CT-AMT-060-01 Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B
Hemophilia A or B CSL689_2001 Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors Cancelled
PICC-associated Thrombosis
A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line Withdrawn
Sickle Cell CSL200_1001 CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
Von Willebrand Disease CSLCT-BIO-12-83 Study of Voncento®in Subjects With Von Willebrand Disease Completed
Cardiovascular and Metabolic Coronary Heart Disease CSL112_1001 Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults Completed
Renal Impairment and Acute Myocardial Infarction CSL112_2001 A Phase 2 Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Moderate Renal Impairment and Acute Myocardial Infarction Results
Acute Myocardial Infarction CSLCT-HDL-12-77
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
Immunology and Neurology
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IgPro20_3004
Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1)

Hereditary Angioedema (HAE) CSL312_2001
A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
  Hereditary Angioedema (HAE)
CSL312_3001 CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

Hereditary Angioedema (HAE)
CSL830_2001 A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Hereditary Angioedema (HAE)
CSL830_3001 A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
Hereditary Angioedema (HAE) CSL830_3002 A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Results

Hereditary Angioedema (HAE)
A Phase 3 study to evaluate clinical efficacy, safety, and pharmacokineti00cs of subcutaneous administration of human plasma derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema in Japanese subjects
HIV-1 CAL-USA-11 An Adaptive Phase I/II Study of the Safety of CAL-USA-11 in HIV-1 Infected Adults Previously Exposed to ART Results
Primary Immune Deficiency (PID) IgPro20_1001 Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump Results
Primary Immune Deficiency (PID) IgPro20_4004 Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID) Results
Primary Immune Deficiency(PID) IgPro20_4005 Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (Hizentra®) on Weekly and Biweekly Schedules Results
Systemic Sclerosis IgPro10_2001 Efficacy and safety study of IgPro10 in adults with Systemic Sclerosis Withdrawn
  Systemic Sclerosis IgPro20_2001 A study to investigate the safety, tolerability, and pharmacokinetics ofIgPro20in subjects with diffuse cutaneous systemic sclerosis (dcSSc)
Healthy Subjects CSL312_1003 A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults Completed
Healthy Subjects CSL324_1001 Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Completed
Healthy Subjects CSL324_1003 Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects
Healthy Subjects CSL730_1001 Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults
Transplant Antibody-mediated kidney transplant rejection CSL842_3001 Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR)in Adult Renal Transplant Recipients Cancelled

World-Class R&D Network

CSL is a global specialty biotech with a strong commitment to funding research and development of medicines to support its continued growth. We operate as one integrated global research and development organization that assembles coordinated global project teams, drawing together staff from different countries depending on their expertise. Our teams rely on a project management framework that facilitates collaboration across national and cultural boundaries.

CSL Parkville office


CSL Limited
Global Corporate HQ
R&D and Manufacturing

CSL Behring
R&D and Manufacturing

Bio21 Global Research and Translational Medicine Hub

Marburg employees


CSL Behring
R&D and Manufacturing

Kankakee office

United States

CSL Behring
Head Office and R&D

CSL Behring
R&D and Manufacturing

CSL Behring
R&D Global Cell & Gene Therapy Research Hub

Bern, Switzerland


CSL Behring
R&D and Manufacturing

Researchers taking notes


CSL Behring

Asian male and caucasian female in a lab


R&D and Manufacturing

R&D Briefings Archives

R&D Briefing  October 2021  file 
R&D Briefing  October 2020  file 
R&D Briefing  December 2019  file 
R&D Briefing  December 2018  file 
R&D Briefing  December 2017  file
R&D Briefing December 2016 file
R&D Briefing December 2015 file
R&D Briefing December 2014 file
R&D Briefing December 2013 file